What is SARD (systemic autoimmune rheumatic disease)?

What is SARD (Systemic Autoimmune Rheumatic Disease)?

SARD refers to systemic autoimmune rheumatic diseases—a category of autoimmune conditions characterized by the potential to affect multiple organ systems and the production of autoantibodies, particularly anti-nuclear antibodies (ANAs). 1

Defining Characteristics

SARDs are distinguished by:

• Multi-organ involvement with systemic manifestations beyond a single anatomic site 2, 3
• Production of autoantibodies, especially ANAs, which serve as serological hallmarks of these conditions 4, 3
• Immune dysregulation with inflammation and/or fibrosis affecting various tissues 1

Specific Diseases Included in SARD Classification

The term SARD encompasses several distinct conditions, with the American College of Rheumatology specifically identifying five diseases at highest risk for interstitial lung disease complications 1, 5, 1:

• Systemic sclerosis (SSc) - affects >50% with ILD, leading cause of death in this population 1
• Rheumatoid arthritis (RA) - ILD is a major cause of mortality 1
• Idiopathic inflammatory myopathies (IIM) - includes polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome 1, 6
• Mixed connective tissue disease (MCTD) - characterized by combination of SLE, SSc, and myositis features with anti-U1-RNP antibodies 7
• Sjögren disease (SjD) - at risk for progressive ILD 1

Additional conditions recognized as SARDs include systemic lupus erythematosus (SLE), which shows the highest prevalence at 3.2% among suspected SARD patients 8.

Clinical Significance and Morbidity

The importance of recognizing SARDs lies in their substantial impact on mortality and quality of life:

• Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality across multiple SARDs, with some patients at risk for rapidly progressive disease requiring mechanical ventilation within days to weeks 1, 9
• Cardiac involvement through macrovascular disease, microvascular dysfunction, and myocarditis contributes to heart failure risk, particularly in SLE, RA, SSc, eosinophilic granulomatosis with polyangiitis, and sarcoidosis 2
• Systemic inflammation affects quality of life through joint involvement, skin manifestations, and constitutional symptoms 7, 3

Diagnostic Approach

Autoantibody testing serves as a critical diagnostic adjunct when used appropriately 3:

• ANA testing by indirect immunofluorescence (IIFA) remains the gold standard for initial screening, with the American College of Rheumatology emphasizing its historical role in disease classification criteria 4
• Disease-specific autoantibodies provide diagnostic precision: anti-dsDNA and anti-Sm for SLE; anti-Scl-70 for SSc; anti-Jo-1 and other anti-synthetase antibodies for IIM 1, 8
• Important caveat: ANA positivity alone does not establish SARD diagnosis—healthy individuals can be ANA-positive, and only 11.8% of patients suspected of having SARD actually receive a confirmed diagnosis 4, 8

Immunological Distinction Between Disease and Health

The transition from asymptomatic ANA positivity to clinical SARD involves a critical shift in immune balance 10:

• Asymptomatic ANA-positive individuals maintain active immunoregulation with increased T regulatory subsets and TGF-β1 10
• SARD patients demonstrate impaired immunoregulation with increased Th2 and Th17 helper cells, pro-inflammatory monocytes, and CD14+ myeloid dendritic cells 10
• This represents a shift from regulatory to inflammatory predominance that distinguishes clinical disease from benign autoantibody production 10

Clinical Implications for Management

Recognition of SARD diagnosis triggers specific management pathways:

• Screening for organ involvement, particularly ILD in high-risk SARDs, using pulmonary function tests and high-resolution chest CT 1, 5
• Risk stratification based on disease-specific factors: anti-Scl-70 positivity and diffuse cutaneous subtype in SSc; high-titer RF and smoking in RA; anti-synthetase antibodies in IIM 1
• Co-management between rheumatology and pulmonology for SARD-associated ILD to optimize outcomes 1, 5